PortalPublikationenImmunosuppressive therapy for aplastic anemia in children: a...

Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival.

Standard

Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. / Führer, Monika; Rampf, Udo; Baumann, Irith; Faldum, Andreas; Niemeyer, Charlotte; Janka-Schaub, Gritta; Friedrich, Wilhelm; Ebell, Wolfram; Borkhardt, Arndt; Bender-Goetze, Christine.

in: BLOOD, Jahrgang 106, Nr. 6, 6, 2005, S. 2102-2104.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Führer, M, Rampf, U, Baumann, I, Faldum, A, Niemeyer, C, Janka-Schaub, G, Friedrich, W, Ebell, W, Borkhardt, A & Bender-Goetze, C 2005, 'Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival.', BLOOD, Jg. 106, Nr. 6, 6, S. 2102-2104. <http://www.ncbi.nlm.nih.gov/pubmed/15933058?dopt=Citation>

APA

Führer, M., Rampf, U., Baumann, I., Faldum, A., Niemeyer, C., Janka-Schaub, G., Friedrich, W., Ebell, W., Borkhardt, A., & Bender-Goetze, C. (2005). Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. BLOOD, 106(6), 2102-2104. [6]. http://www.ncbi.nlm.nih.gov/pubmed/15933058?dopt=Citation

Vancouver

Führer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. BLOOD. 2005;106(6):2102-2104. 6.

Bibtex

@article{aa6a8cbcff0a45c5a6c97f76d3f073b6,
title = "Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival.",
abstract = "Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by pancytopenia and hypoplastic bone marrow. Autologous T lymphocytes are thought to cause bone marrow failure by immune-mediated excessive apoptosis of stem and progenitor cells. The disease is subclassified into a severe (neutrophil count, > 0.2 x 10(9)/L [> 200/microL]) and a very severe (<0.2 x 10(9)/L [<200/microL]) (vSAA) form. We report the results of a prospective multicenter trial with a combined immunosuppressive regimen of cyclosporin A (CSA), anti-thymocyte globulin (ATG) and, in cases with neutrophil counts fewer than 0.5 x 10(9)/L (<500/microL), granulocyte colony-stimulating factor (G-CSF) for treatment of SAA in children. Children with vSAA showed a higher rate of complete response than did children with SAA (68% versus 45%; P = .009), as well as better survival (93% versus 81%; P <.001). Thus, in children with SAA a more severe disease stage at diagnosis indicates a favorable outcome with immunosuppressive therapy.",
author = "Monika F{\"u}hrer and Udo Rampf and Irith Baumann and Andreas Faldum and Charlotte Niemeyer and Gritta Janka-Schaub and Wilhelm Friedrich and Wolfram Ebell and Arndt Borkhardt and Christine Bender-Goetze",
year = "2005",
language = "Deutsch",
volume = "106",
pages = "2102--2104",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

RIS

TY - JOUR

T1 - Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival.

AU - Führer, Monika

AU - Rampf, Udo

AU - Baumann, Irith

AU - Faldum, Andreas

AU - Niemeyer, Charlotte

AU - Janka-Schaub, Gritta

AU - Friedrich, Wilhelm

AU - Ebell, Wolfram

AU - Borkhardt, Arndt

AU - Bender-Goetze, Christine

PY - 2005

Y1 - 2005

N2 - Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by pancytopenia and hypoplastic bone marrow. Autologous T lymphocytes are thought to cause bone marrow failure by immune-mediated excessive apoptosis of stem and progenitor cells. The disease is subclassified into a severe (neutrophil count, > 0.2 x 10(9)/L [> 200/microL]) and a very severe (<0.2 x 10(9)/L [<200/microL]) (vSAA) form. We report the results of a prospective multicenter trial with a combined immunosuppressive regimen of cyclosporin A (CSA), anti-thymocyte globulin (ATG) and, in cases with neutrophil counts fewer than 0.5 x 10(9)/L (<500/microL), granulocyte colony-stimulating factor (G-CSF) for treatment of SAA in children. Children with vSAA showed a higher rate of complete response than did children with SAA (68% versus 45%; P = .009), as well as better survival (93% versus 81%; P <.001). Thus, in children with SAA a more severe disease stage at diagnosis indicates a favorable outcome with immunosuppressive therapy.

AB - Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by pancytopenia and hypoplastic bone marrow. Autologous T lymphocytes are thought to cause bone marrow failure by immune-mediated excessive apoptosis of stem and progenitor cells. The disease is subclassified into a severe (neutrophil count, > 0.2 x 10(9)/L [> 200/microL]) and a very severe (<0.2 x 10(9)/L [<200/microL]) (vSAA) form. We report the results of a prospective multicenter trial with a combined immunosuppressive regimen of cyclosporin A (CSA), anti-thymocyte globulin (ATG) and, in cases with neutrophil counts fewer than 0.5 x 10(9)/L (<500/microL), granulocyte colony-stimulating factor (G-CSF) for treatment of SAA in children. Children with vSAA showed a higher rate of complete response than did children with SAA (68% versus 45%; P = .009), as well as better survival (93% versus 81%; P <.001). Thus, in children with SAA a more severe disease stage at diagnosis indicates a favorable outcome with immunosuppressive therapy.

M3 - SCORING: Zeitschriftenaufsatz

VL - 106

SP - 2102

EP - 2104

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 6

M1 - 6

ER -